SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today reported its fourth quarter and full-year 2025 operating and financial results and reviewed recent business highlights.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
